- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Economist Michael Decter Lists Mettrum as a "Top Pick" on BNN's Market Call.
A recent article on BNN market Call highlighted Mettrum Health Corp. (TSXV:MT.V).
A recent article on BNN market Call highlighted Mettrum Health Corp. (TSXV:MT.V).
As quoted in the article:
Canada faces a major political challenge in determining whether there is the political will to build any pipelines in the face of determined, although not unified, opposition from environmental and Indigenous groups. For a federal government committed to rebuilding infrastructure, it is odd that oil by rail as the default choice would be acceptable.
We are in a lower-for-longer economic environment in terms of economic growth, interest rates and commodity prices. However, we expect a strong finish to 2016 in North American equity markets following the U.S. presidential election.
Top Picks
Mettrum Health (MT.V)
- Mettrum has 16,000 patients and has established itself as one of, if not the, strongest medicinal players. Company has perhaps the best reputation amongst physician community.
- Industry is growing at 10 per cent month-over-month and Mettrum is maintaining its market share of approximately 12 to 15 per cent.
- Company is fully licensed at two facilities with limitless ability to increase capacity.
- Running at 70 per cent gross margins.
- Cash of over $30 million.
- Well positioned to participate in recreational market, which is expected to be rolled out next year.
- Company has a market cap of $150 million versus Canopy at $460 million, despite Canopy having 2,000 patients and similar operating metrics to Mettrum.
- Aphria has half the patients and twice the market cap.
- Handful of other new entrants with a fraction of the business of MT also trade at $150 million market cap.
- Massive valuation discrepancy between MT and the other players.
- Starting to think this space if getting a bit ahead of itself, but Mettrum continues to look like exceptional value and the best way to play the space.
Connect with Mettrum Health Corp. (TSXV:MT.V)  to receive an Investor Presentation.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.Â